Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3903 ARTÍCULOS , VIENDO DEL 2536 AL 2550

TRPC1

Nesin V, Tsiokas L.

Handb Exp Pharmacol. 2014;222:15-51. doi: 10.1007/978-3-642-54215-2_2.

The cognitive burden in Huntington's disease: pathology, phenotype, and mechanisms of compensation

Papoutsi M, Labuschagne I, Tabrizi SJ, Stout JC.

Mov Disord. 2014 Apr 15;29(5):673-83. doi: 10.1002/mds.25864.

Cognitive impairment in "Other" movement disorders: hidden defects and valuable clues

Walterfang M, van de Warrenburg BP.

Mov Disord. 2014 Apr 15;29(5):694-703. doi: 10.1002/mds.25849.

Amyotrophic lateral sclerosis in a patient with a family history of huntington disease: genetic counseling challenges

Smith AL, Teener JW, Callaghan BC, Harrington J, Uhlmann WR.

J Genet Couns. 2014 Oct;23(5):725-33. doi: 10.1007/s10897-014-9715-6. Epub 2014 Apr 26.

Risk-taking and pathological gambling behavior in Huntington's disease

Kalkhoven C, Sennef C, Peeters A, van den Bos R.

Front Behav Neurosci. 2014 Apr 2;8:103. doi: 10.3389/fnbeh.2014.00103. eCollection 2014.

Defining the limits: Protein aggregation and toxicity in vivo

Holmes WM, Klaips CL, Serio TR.

Crit Rev Biochem Mol Biol. 2014 Jul-Aug;49(4):294-303. doi: 10.3109/10409238.2014.914151. Epub 2014 Apr 28.

Infantile epileptic encephalopathy with a hyperkinetic movement disorder and hand stereotypies associated with a novel SCN1A mutation

Ohashi T, Akasaka N, Kobayashi Y, Magara S, Kawashima H, Matsumoto N, Saitsu H, Tohyama J.

Epileptic Disord. 2014 Jun;16(2):208-12. doi: 10.1684/epd.2014.0649.

Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders [RETIRED]: report of the Guideline Development Subcommittee of the American Academy of Neurology

Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D.

Neurology. 2014 Apr 29;82(17):1556-63. doi: 10.1212/WNL.0000000000000363.

Huntington's disease: from disease mechanisms to therapies

Blackstone C.

Drug Discov Today. 2014 Jul;19(7):949-50. doi: 10.1016/j.drudis.2014.04.013. Epub 2014 Apr 30.

Mood disorders in Huntington's disease: from behavior to cellular and molecular mechanisms

Pla P, Orvoen S, Saudou F, David DJ, Humbert S.

Front Behav Neurosci. 2014 Apr 23;8:135. doi: 10.3389/fnbeh.2014.00135. eCollection 2014.

The iron regulatory capability of the major protein participants in prevalent neurodegenerative disorders

Wong BX, Duce JA.

Front Pharmacol. 2014 Apr 21;5:81. doi: 10.3389/fphar.2014.00081. eCollection 2014.

[Case report; Chorea as the first manifestation of systemic lupus erythematosus associated with anti-phospholipid syndrome]

Sasaki H, Ito K, Furusaki A, Amasaki Y, Abe T.

Nihon Naika Gakkai Zasshi. 2014 Mar 10;103(3):744-6. doi: 10.2169/naika.103.744.

Autophagy of mitochondria: a promising therapeutic target for neurodegenerative disease

Kamat PK, Kalani A, Kyles P, Tyagi SC, Tyagi N.

Cell Biochem Biophys. 2014 Nov;70(2):707-19. doi: 10.1007/s12013-014-0006-5.

Cofilin/actin rod formation by dysregulation of cofilin-1 activity as a central initial step in neurodegeneration

Schönhofen P, de Medeiros LM, Chatain CP, Bristot IJ, Klamt F.

Mini Rev Med Chem. 2014 May;14(5):393-400. doi: 10.2174/1389557514666140506161458.

Polyglutamine (PolyQ) diseases: genetics to treatments

Fan HC, Ho LI, Chi CS, Chen SJ, Peng GS, Chan TM, Lin SZ, Harn HJ.

Cell Transplant. 2014;23(4-5):441-58. doi: 10.3727/096368914X678454.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias